SenesTech, a leader in rodent birth control solutions, will participate in the Lytham Partners Fall 2026 Investor Conference virtually on September 29-30, 2026. The company will host a webcast presentation and one-on-one investor meetings to discuss its sustainable rodent population management products. This event offers investors a chance to learn about SenesTech's patented Evolve® and ContraPest® brands and their role in pest control. The webcast will be available live and for replay after the event.
SenesTech's upcoming participation in the Lytham Partners Fall 2026 Investor Conference is noted here with Pluang's Consumer Staples sector data as context. Of 46 priced US stocks in this sector on Pluang, 22 rose and 24 fell as of September 18, 2026, 03:42 WIB. Notable movers include Funko Inc (FNKO) at USD 5.38 with a 2.38% increase and 100% sell order activity, and Lamb Weston Holdings Inc (LW) at USD 46.44 with a 2.29% decrease and 100% buy order activity.
Callan JMB has received and will install a QuickStrip™ oral thin-film production line from Rapid Dose Therapeutics at its Texas facility, marking a key step in expanding its domestic pharmaceutical manufacturing. This new capability aims to produce f...
Known, a company developing accountability infrastructure for autonomous AI, announced that Edna Conway, former senior security executive at Microsoft and Cisco, has joined its Advisory Council. Conway brings extensive experience in cybersecurity and...
A SEON survey of 2,026 U.S. adults reveals that while 68% use AI agents weekly for personal tasks, half are uncomfortable letting AI handle credit card purchases. Only 15% would share financial info with AI, and 43% lack confidence in spotting fraudu...
Radiopharm Theranostics announced progress in its oncology radiopharmaceutical pipeline, including preparing for a pivotal Phase 3 imaging trial of RAD101 for recurrent brain metastases after a successful FDA End-of-Phase 2 meeting. The company also ...
UroGen Pharma has dosed the first patient in a Phase 1 trial testing UGN-501, a next-generation oncolytic virus for non-muscle invasive bladder cancer (NMIBC). The trial aims to evaluate the safety and tolerability of UGN-501 administered directly in...
